Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
norgestimate and ethinyl estradiol
Overview
What is Tri Femynor?
Tri Femynor™ (norgestimate and ethinyl estradiol tablets, USP) is a combination oral contraceptive containing the progestational compound norgestimate and the estrogenic compound ethinyl estradiol. Norgestimate, USP is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)-(+)-) and ethinyl estradiol, USP is designated as (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol).
What does Tri Femynor look like?







What are the available doses of Tri Femynor?
Tri Femynor consists of 28 round, biconvex, film-coated tablets in the following order :
What should I talk to my health care provider before I take Tri Femynor?
Nursing mothers: Not recommended; can decrease milk production.
How should I use Tri Femynor?
Tri Femynor Tablets are indicated for use by females of reproductive potential to prevent pregnancy [].
Tri Femynor tablets are dispensed in a blister pack []. Tri Femynor may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.
What interacts with Tri Femynor?
Sorry No Records found
What are the warnings of Tri Femynor?
Sorry No Records found
What are the precautions of Tri Femynor?
Sorry No Records found
What are the side effects of Tri Femynor?
Sorry No records found
What should I look out for while using Tri Femynor?
Do not prescribe Tri Femynor to women who are known to have the following conditions:
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [].
What might happen if I take too much Tri Femynor?
There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.
How should I store and handle Tri Femynor?
Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].Dispense in tight container as defined in the USP, with a child-resistant closure (as required).Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].Dispense in tight container as defined in the USP, with a child-resistant closure (as required).16.1 How Supplied Duloxetine Delayed-release Capsules are available as delayed release capsules in the following strengths, colors, imprints, and presentations: Features Strengths 20 mg* 30 mg* 60 mg* * equivalent to duloxetine base Body color Opaque ochre Opaque white Opaque ochre Cap color Opaque ochre Opaque green Opaque green Cap imprint B B B Body imprint 746 747 748 Presentations and NDC Codes Bottles of 30 NA 51991-747-33 51991-748-33 Bottles of 60 51991-746-06 NA NA Bottles of 90 51991-746-90 51991-747-90 51991-748-90 Bottles of 500 51991-746-05 NA NA Bottles of 1000 NA 51991-747-10 51991-748-10 16.2 Storage and Handling Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. 16.1 How Supplied Duloxetine Delayed-release Capsules are available as delayed release capsules in the following strengths, colors, imprints, and presentations: Features Strengths 20 mg* 30 mg* 60 mg* * equivalent to duloxetine base Body color Opaque ochre Opaque white Opaque ochre Cap color Opaque ochre Opaque green Opaque green Cap imprint B B B Body imprint 746 747 748 Presentations and NDC Codes Bottles of 30 NA 51991-747-33 51991-748-33 Bottles of 60 51991-746-06 NA NA Bottles of 90 51991-746-90 51991-747-90 51991-748-90 Bottles of 500 51991-746-05 NA NA Bottles of 1000 NA 51991-747-10 51991-748-10 16.2 Storage and Handling Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.
Acne is a skin condition with a multifactorial etiology, including androgen stimulation of sebum production. While the combination of ethinyl estradiol and norgestimate increases sex hormone-binding globulin (SHBG) and decreases free testosterone, the relationship between these changes and a decrease in the severity of facial acne in otherwise healthy women with this skin condition has not been established.
Non-Clinical Toxicology
Do not prescribe Tri Femynor to women who are known to have the following conditions:Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [].
Thromboembolic Disorders and Other Vascular Problems
Liver disease
High blood pressure
Carbohydrate and lipid metabolic effects
Headache
Bleeding Irregularities and Amenorrhea
The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling:
Adverse reactions commonly reported by COC users are:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).